| Drug Name |
Eslicarbazepine acetate |
| Drug ID |
BADD_D00812 |
| Description |
Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. Eslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of voltage-gated sodium channels, thus preventing their return to the activated state during which seizure activity can occur.
Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food. Eslicarbazepine acetate is associated with numerous side effects including dizziness, drowsiness, nausea, vomiting, diarrhea, headache, aphasia, lack of concentration, psychomotor retardation, speech disturbances, ataxia, depression and hyponatremia. It is recommended that patients taking eslicarbazepine acetate be monitored for suicidality. |
| Indications and Usage |
Eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients. |
| Marketing Status |
Prescription |
| ATC Code |
N03AF04 |
| DrugBank ID |
DB09119
|
| KEGG ID |
D09612
|
| MeSH ID |
C416835
|
| PubChem ID |
179344
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
76072-1005; 70966-0007; 63402-202; 63402-248; 42419-026; 59651-482; 63402-206; 66406-0222; 66406-0327; 63402-208; 63402-204; 52076-6269; 66406-0204; 55111-933; 65372-1170; 66406-0203; 69766-051 |
| Synonyms |
eslicarbazepine acetate | 10-acetoxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide | BIA 2-093 | BIA-2-093 | Zebinix | Aptiom |
